

Supplemental Table 1. Key Inclusion and Exclusion Criteria.

Inclusion criteria
<ul style="list-style-type: none">• Male or female aged 18 years or older• Type 1 or type 2 Diabetes Mellitus• CI-DME with CST of $\geq 320\mu\text{m}$ on Spectralis® SD-OCT• BCVA ≤ 62 and ≥ 23 ETDRS letter score in the study eye• History of response to anti-VEGF agents and/or corticosteroids and, in the opinion of the Investigator, remained responsive to treatment• Written informed consent obtained from the subject prior to screening procedures
Exclusion criteria
<ul style="list-style-type: none">• Macular edema due to causes other than DME• Concurrent disease in the study eye, other than CI-DME, that could compromise BCVA, require medical or surgical intervention during the study period or could confound interpretation of the results• Any condition that could confound the ability to detect a change in CST in the study eye• Previous confounding treatments / procedures, or expected to require confounding treatments / procedures at any time during the study period• Presence of neovascularization at the disc in the study eye• Uncontrolled glaucoma in the study eye• Any active ocular / intra-ocular infection or inflammation in either eye• Poorly controlled Diabetes Mellitus• Uncontrolled hypertension

BCVA = best-corrected visual acuity; CI-DME = center-involved diabetic macular edema; CST = central subfield thickness; DME = diabetic macular edema; ETDRS = international clinical diabetic retinopathy disease severity scale; SD-OCT = spectral domain optical coherence tomography